CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/-- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that Michael J. Astrue,
President and Chief Executive Officer will present at two upcoming
conferences: Banc of America's New Products, New Paradigms in Health Care
Conference being held July 28-30, 2004 in Southampton, New York and Robert W.
Baird's 2004 Small Cap Conference being held August 4-5, 2004 in New York, New
York.
Mr. Astrue will present at Banc of America's conference at 1:30 p.m.
Eastern Time on Thursday, July 29, 2004. This presentation will focus on TKT's
Hunter syndrome and Gaucher disease programs. In addition, he will
participate in a panel discussion on generic biologics at Banc of America on
Thursday, July 29, 2004 at 3:00 p.m. Eastern Time. Mr. Astrue will also
present an overview of TKT's business activities at 1:20 p.m. Eastern Time on
August 5, 2004 at the Robert W. Baird conference.
A live audio webcast of these presentations will be available at
http://www.tktx.com on TKT's Investor Information website under the Events
category. A replay of the Banc of America presentation and panel discussion
will be available until August 12, 2004 and a replay of the Robert W. Baird
presentation will be available until August 19, 2004.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
Latin America. Additional information about TKT is available on the
company's website at http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Aventis Pharmaceuticals, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Manager, Transkaryotic Therapies, Inc., +1-617-349-0205
Logo: NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO AP Archive:
http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or
212-782-2840
|
